IP Library Granted Patent US 10,688,049
Granted Patent B2
US 10,688,049 · App. 15/031,519 · Granted Jun 23, 2020

Process for the preparation of a freeze-dried pharmaceutical composition containing mitomycin C

Inventors: Sonja Schuldt-Lieb (Hamburg, DE); Sebastian Bialleck (Hamburg, DE); Ingo Guhde (Hamburg, DE); Michaela Rehberg (Hamburg, DE)
Assignee: MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH
A61K9/19A61K9/0019A61K9/08A61K9/1617A61K9/1623A61K9/1641A61K31/407A61K47/10A61K47/18A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,688,049
App. No.
15/031,519
Granted
Jun 23, 2020
Kind
B2
Abstract

A process is described for the preparation of freeze-dried pharmaceutical compositions of mitomycin C, which are characterized by high stability and can be rapidly reconstituted to form solutions.

Claims (7)

1. Process for the preparation of a freeze-dried pharmaceutical composition comprising mitomycin C, comprising freeze-drying a solution of mitomycin C, wherein the solution comprises a mixture of tert.-butanol and water, which mixture comprises 84 to 95 wt. % tert.-butanol.

2. Process according to claim 1 , in which the solution comprises mitomycin C at a concentration of 0.1 to 500 mg per gram of the solution.

3. Process according to claim 1 , in which the solution additionally comprises at least one additive selected from the group of urea, polyethylene glycol and mannitol.

4. Process according to claim 3 , in which the solution comprises urea at a concentration of 1 to 200 mg per gram of the solution.

5. Process according to claim 3 , in which the polyethylene glycol has an average molecular weight (number average) of 1000 to 8000 and preferably of 2000 to 8000.

6. Process according to claim 3 , in which the solution comprises polyethylene glycol at a concentration of 1 to 200 mg/g.

7. Process according to claim 3 , in which the solution comprises mannitol at a concentration of 1 to 200 mg/g.

Assignments (3)
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Mar 2, 2026
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 074994/0338 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Mar 6, 2025
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC [COLLATERAL AGENT]
Reel/Frame 070434/0319 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2016
From: SCHULDT-LIEB, SONJA; BIALLECK, SEBASTIAN; GUHDE, INGO; REHBERG, MICHAELA
To: MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH
Reel/Frame 038506/0931 →
Priority Claims (1)
EP 13189775 · Oct 22, 2013 · regional
Continuity (1)
Related Publication 20160256391A1 · Sep 8, 2016